Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07775404 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus

Study acronym: Elecoglipron
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Jun 4, 2027 → Apr 6, 2028
See other at-risk trials from AstraZeneca

Record History

  1. Primary completion pushed from Jun 4, 2027 to Apr 6, 2028 Completion date: Apr 20, 2028 to Apr 13, 2028 · Eligibility criteria expanded, about 14 words · Site details revised at 32 of 49 sites Show 3 more changesShow less
    • Completion date: Apr 20, 2028 to Apr 13, 2028
    • Eligibility criteria expanded, about 14 words
    • Site details revised at 32 of 49 sites
  2. Recruitment opened Primary completion moved earlier from Apr 20, 2028 to Jun 4, 2027 · Start date changed from estimate of Aug 28, 2026 to Aug 21, 2026 · Site details revised at 49 of 49 sitesv2 Show 3 more changesShow less
    • Primary completion moved earlier from Apr 20, 2028 to Jun 4, 2027
    • Start date changed from estimate of Aug 28, 2026 to Aug 21, 2026
    • Site details revised at 49 of 49 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.
Trial Details
NCT Number NCT07775404
Lead Sponsor AstraZeneca
Conditions Obesity, Overweight
Enrollment 351 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov